Dr. Brawer on the Prolaris Genetic Test in Predicting Prostate Cancer Aggressiveness

Michael Brawer, MD
Published: Monday, May 22, 2017



Michael Brawer, MD, vice president of Medical Affairs, Myriad Genetic Laboratories, discusses the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.

According to Brawer, African Americans have the highest rate of prostate cancer in the world and tend to present with more aggressive cancer.

The Prolaris test is done on the diagnostic biopsy and has been shown to provide a much more precise risk assessment as to the risk of biochemical recurrence, the development of metastases, or disease-specific mortality. This test has been shown to work across all risk groups, explains Brawer.
 


Michael Brawer, MD, vice president of Medical Affairs, Myriad Genetic Laboratories, discusses the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.

According to Brawer, African Americans have the highest rate of prostate cancer in the world and tend to present with more aggressive cancer.

The Prolaris test is done on the diagnostic biopsy and has been shown to provide a much more precise risk assessment as to the risk of biochemical recurrence, the development of metastases, or disease-specific mortality. This test has been shown to work across all risk groups, explains Brawer.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x